<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000801</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 252</org_study_id>
    <secondary_id>ECOG E 1493</secondary_id>
    <nct_id>NCT00000801</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To estimate the response rate, overall and disease-free survival, toxicities, factors&#xD;
      associated with outcome, and effect on quality of life in patients with AIDS-related primary&#xD;
      CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and&#xD;
      dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external&#xD;
      beam irradiation. To determine other clinical markers present in this patient population.&#xD;
&#xD;
      Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS&#xD;
      lymphoma.&#xD;
&#xD;
      Patients who upon staging workup are found to be without systemic involvement undergo one&#xD;
      cycle of chemotherapy with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and&#xD;
      G-CSF. Cyclophosphamide, doxorubicin, and vincristine are administered intravenously on day&#xD;
      1. Dexamethasone is administered intravenously on day 1 and then orally thereafter with&#xD;
      gradual discontinuation. G-CSF is administered subcutaneously daily beginning on day 2 and&#xD;
      continuing for a total of 10 days or until blood counts have recovered to an acceptable&#xD;
      level. Patients with evidence of cancer cells in their cerebrospinal fluid (CSF) will receive&#xD;
      chemotherapy with intrathecal cytarabine twice weekly until no further evidence of cancer&#xD;
      cells is found in the CSF, then once weekly for 6 weeks, and then monthly for 10 months.&#xD;
      Seven to ten days following completion of one cycle of chemotherapy, patients undergo&#xD;
      radiotherapy to the brain at a dose of 2.5 Gy daily for 5 days per week for approximately 4&#xD;
      weeks. Total dose to the whole brain and meninges is 30.0 Gy in 12 fractions, and total dose&#xD;
      to the primary boost volume is 10.0 Gy in 4 fractions. During therapy, blood is drawn weekly&#xD;
      and brain scans are performed every 3-12 weeks. An initial CSF sample will be obtained by&#xD;
      lumbar puncture.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1998</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>33</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication: Required:&#xD;
&#xD;
          -  PCP prophylaxis with Bactrim, dapsone, or aerosolized pentamidine.&#xD;
&#xD;
          -  Oral candidiasis prophylaxis with fluconazole, ketoconazole, or clotrimazole oral&#xD;
             troches.&#xD;
&#xD;
          -  Antiretroviral agent available by therapy IND.&#xD;
&#xD;
          -  MAI prophylaxis with rifabutin (in patients with CD4 counts &lt; 100 cells/mm3).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Primary CNS lymphoma with NO systemic involvement.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior corticosteroids.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Concomitant malignancy other than Kaposi's sarcoma, curatively treated carcinoma in&#xD;
             situ of the cervix, or squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Renal failure, active nonmalignant duodenal ulcer, uncontrolled diabetes mellitus, or&#xD;
             other serious medical conditions that would preclude aggressive cytotoxic chemotherapy&#xD;
             administration.&#xD;
&#xD;
          -  Active heart disease (congestive heart failure or heart block greater than first&#xD;
             degree on EKG).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any investigational agent other than antiretroviral agents available by therapy IND.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  No prior malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ&#xD;
             of the cervix, or squamous cell or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  No new infectious complications within the past 2 weeks that require a change in&#xD;
             antibiotics.&#xD;
&#xD;
          -  History of myocardial infarction within the past 3 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior chemotherapy other than for Kaposi's sarcoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krigel RL</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Von Roenn J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - West Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ECOG Data Management Office</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996 Feb;14(2):556-64. doi: 10.1200/JCO.1996.14.2.556.</citation>
    <PMID>8636771</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <keyword>Vincristine</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Granulocyte Colony-Stimulating Factor</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <keyword>Brain Neoplasms</keyword>
  <keyword>Lymphoma, High-Grade</keyword>
  <keyword>Lymphoma, Intermediate-Grade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

